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Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder 
characterized by a greatly increased susceptibility to severe fungal and bacterial infections 
caused by defects in NADPH oxidase of phagocytic cells. We aimed to investigate 
immunophenotype alterations of naïve and memory B cells and B1a cells in peripheral whole 
blood from Iranian patients with CGD. 
Flow cytometric analysis was performed on peripheral blood samples from 31 CGD 
patients and 23 healthy controls (HC) to study naïve (IgD+/CD27-), memory (CD27+) B 
and B1a (CD5+) cells. Soluble CD27 (sCD27) and immunoglobulins were also measured by 
ELISA and the nephelometric method, respectively. 
We found significantly higher levels of naïve B cells and B1a cells but lower levels of 
memory B cells in CGD patients compared to HC. There was no significant difference in 
soluble CD27 (sCD27) alteration between CGD patients and HC. 
Our findings suggested a role for NADPH oxidase in process of B cell differentiation and 
impairing conversion of naïve B cells to memory B cells and altered B1a cells in CGD 
patients. Increased susceptibility of CGD patients to opportunistic infections and 
autoimmune disorders could be partly explained by the altered phenotype of B lymphocytes 
in these patients. 
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Chronic granulomatous disease (CGD) is a disease 
of impaired phagocytosis, as neutrophils and 
monocytes from CGD patients fail to exhibit an 
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increase in oxygen metabolism during phagocytosis.1 
The disease is a rare genetic disorder (minimum 
estimated prevalence of 1/200,000 to 1/250,000) in the 
innate immune system characterized by severe and 
recurrent infections with mostly catalase-positive 
microorganisms. In these patients, phagocytes are not 
able to mount a respiratory burst to kill invading 
bacteria and fungi.2 CGD is genetically caused by 
mutations in any of four proteins of the NADPH 
oxidase complex, including: gp91phox, p22phox (both 
subunits of the membrane cytochrome b558), p47phox, 
and p67phox (the cytosolic components of the enzyme 
complex).3 Besides, a fifth subunit (namely p40phox), 
was recently known which plays an important role in 
phagocytosis-induced superoxide production.4 Defect 
in gp91phox subunit results in X-linked (XL) and 
defect in any of the other subunits results in autosomal 
recessive (AR) type of the disease. 
Interestingly, the presence of the phagocyte O- 
generating NADPH oxidase in B cells is also well 
established. In these cells, the activity of NADPH 
oxidase is different from that in professional 
phagocytes; for instance, oxidants generated at low 
levels can act as signaling molecules.5 However, it has 
been shown that B cells also produce superoxide in 
response to various stimuli,6 but these B cells produce 
only a small amount of superoxide even when fully 
stimulated.7 The nature of components of the NADPH 
oxidase system and the mode of interaction appear to 
be the same in neutrophils and B lymphocytes. 
However, the rate of production of O2- by B 
lymphocytes is ten to twenty times lower than that of 
neutrophils which is probably revealed by the fact that 
cytochrome b558 is much less abundant in B cells 
compared to neutrophils.8 In contrast, B cells contain 
the same order of magnitude of the cytosolic factors of 
p67phox, p47phox and p40phox as those found in 
neutrophils.8,9 B lymphocytes use their slowly 
generated O2- and its direct product of dismutation 
H2O2 for other purposes like acting as second 
messenger in signal transduction pathways.8 
Regarding studying the number of B lymphocytes, 
there is a universal marker for human memory B cells 
which can be used for distinguishing memory cells 
(CD27+) from naïve B cells (CD27-/IgD+).10,11 In 
clinical practice, membrane CD27 and its soluble form 
(sCD27) are used as lymphocyte subset and disease 
markers in the case of lymphoid malignancies, 
autoimmunity and transplant rejection.12 The absence 
of memory B cells as a cause of the impaired 
immunoglobulin production was demonstrated in vivo 
and in vitro in some of the immunodeficiency diseases 
such as common variable immunodeficiency (CVID) 
and X-linked hyper-IgM syndrome (XHIM).13 
CGD patients are at risk for chronic inflammatory 
manifestations and autoimmune diseases, but it is not 
clear whether these disorders are secondary to altered 
superoxide production, or whether a defect in adaptive 
immune system, like defect in B lymphocytes, is 
involved.14 Moreover, we thought whether deficiency 
of NADPH oxidase components occurred in CGD 
patients can also affect their B cells. So, we aimed to 
study phenotype changes of the B cells in peripheral 
blood of patients with CGD using CD27+ B cells (as 
memory B cells marker) and IgD+/CD27- (as naïve B 
cells marker). We also investigated another subset of 
the B cells, defined by CD5 expression (known as B1a 
cells15) which might contribute to the CGD 
pathogenesis. Finally, we studied immunoglobulins 
(IgG, IgM and IgA) and sCD27 serum or plasma levels 
in this CGD population. 
 
MATERIALS AND METHODS 
 
Subjects 
Thirty-one patients with CGD (CGD group) 
consuming cotrimoxazole and in some cases IFN-γ 
and/or itraconazol were included. All patients were 
diagnosed as CGD based on abnormal neutrophil 
oxidative burst assay (nitroblue tetrazolium (NBT) 
slide test and flow cytometry using dihydrorhodamine 
123 (DHR) assay) at Immunology, Asthma and Allergy 
Research Institute; a main referral center for 
immunodeficiency disorder in Iran from December 
2007 to June 2009. All of these patients were registered 
in IPIDR (Iranian Primary Immunodeficiency 
Registry).16,17 The CGD subtypes of the patients were 
also determined by western immunoblot detection of 
cytosolic and membrane NADPH oxidase components 
as described by Fattahi et al18. A healthy control group 
(HC), consisting 23 healthy; 10 males and 13 females, 
with the mean age of 13.2±12.2 years old (age range of 
2-35 yrs), provided reference ranges for lymphocyte 
markers and soluble CD27 (sCD27) levels. We also 
obtained blood from two available XL-CGD carriers. 




Goat anti-human IgD: RPE, Mouse anti-human 
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CD27: FITC, Mouse anti-human CD5: FITC, Mouse 
anti-human CD19: RPE and lysing solution (IQ 
Product Company) were used in the experiments. All 
monoclonal antibodies (mAbs) were purchased from 
AbD Serotec, and used according to the manufacturer’s 
recommendation.  
sCD27 instant ELISA and immunoglobolin kits 
were purchased from the Binding Site company and the 




One milliliter of peripheral blood specimens were 
obtained from patients, and healthy controls. 
Anticoagulated (EDTA) samples were stained using the 
whole blood lysis method and analyzed on FACScan 
flow cytometer (Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA) using CellQuest 
software. Control samples from healthy subjects were 
also analyzed simultaneously with the patients' 
samples. B cell subsets were identified by expression of 
CD19 in all experiments. To analyze subpopulation of 
the B cells, CD27, CD5 and IgD markers were used. At 
the acquisition and analysis steps, lymphocytes were 
selected in a gate by drawing a region around the cell 
population on the forward scatter (FCS)/side scatter 
(SSC) dot plot. Evaluation of expression of surface 
markers was assessed by looking at the relative number 
of positive cells. Isotype control antibodies were used 
to separate positive and negative cells on FITC and PE 
fluorescence channels. 
 
Human sCD27 Instant ELISA 
The Instant ELISA plate for sCD27 contained 
coating antibody and lyophilized detection antibody, 
streptavidin-HRP, and sample diluent. The plate wells 
also contained the ready-to-use standard curve 
containing serially diluted standard protein. So, an anti-
CD27 mAb was coated to polystyrene microtiter wells 
to bind sCD27 present in serum and standard. After 
incubating 3 hours at room temperature and then 
washing, tetramethylbenzidine (TMB) substrate 
solution was added and was incubated for 10 minutes at 
room temperature. After adding stop solution, 
absorbance of patient and control samples and 
standards was measured at 450 nm in an ELISA reader. 
The concentration of sCD27 in serum was determined 
by interpolation with the standard curve, generated 
from seven sCD27 standards, ranging from 0.625 to 20 
U/ml. A reference range was established from 16 




Immunoglobulin serum levels of CGD patients 
were determined by nephelometric methods. The 
immunoglobulin levels (IgG, IgM and IgA) in the 
patients were compared with the normal ranges 
according to their classified age groups19. The age of 
the patients was divided into 7 groups as follows: 
1-<2 years, 2-<3 years, 3-<6 years, 6-<9 years, 9-<12 
years, 12-<16 years and 16 or older than 16 years. 
 
Statistical Analysis 
All data were analyzed using SPSS statistical 
software package version 13 (SPSS Inc, Chicago IL, 
USA). Comparisons between means were performed 
with Mann U Whitney test. Spearman correlation 
coefficient was used to assess relationship between two 
non-normally distributed continuous variables A level 





Thirty-one CGD patients including 14 females 
(45.2%) and 17 males (54.8%) were studied during a 
period of 1.5 years. The mean (± SD) age of  
the patients was 13.2± 8.7 years. Their age range was 
from 1.5 to 34 years old with the median age of  
11 years. Based on the neutrophil function tests done in  
the patients’ mothers, showing a mosaic population  
of oxidase-positive and oxidase negative neutrophils,18 
two patients (6.5%) were recognized to have XL-CGD 
type. The rest of the patients (29 cases; 93.5%)  
had AR-CGD type. Western blot results also confirmed 
these results and revealed subtypes of the AR-CGD 
(Table 1). Among AR-CGDs, 16 cases (55.2%)  
had p47phox defect, 10 cases (34.5%) had p22phox 
defect and 3 cases (10.3%) had p67phox defect.  
Table 1 shows the characteristics of the patients in this 
study. 
 
Flow Cytometric Analysis of B Cell Subpopulations 
We found lower percentage of CD27+/CD19+  
cells (memory B cells) in peripheral blood of the 
patients compared to HC group (p<0.0001) (Figure 
1A). In the CGD group, a median of 1.4% (range of 0-
2.64%) of the B cells were positive for CD27,  
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Table 1. Subtypes of studied CGD patients determined by western immunoblotting 
CGD Subtypes Frequency (%) Sex Age (years) 
AR-CGD 29 (93.5%) 12 M, 17 F 13.6± 8.8 
13 (1.5-34) 
p47phox 16 (55.2%) 5 M, 11 F 16.7± 9.1 
17.5 (4-34) 
p67phox 3 (10.3%) 1 M, 2 F 3.5± 2.3 
3 (1.5-6) 




2 (6.5%) 2 M 7.9± 5.8 
7.9 (3.8-12) 
*Age data is presented as mean±SD and median (min-max). 












































Figure 1. Percentage of CD27 expression (CD27+) on B 
cells in 31 CGD patients and 23 healthy control (HC) 






































Figure 2. Percentage of IgD expression (IgD+/CD27-) on B 
cells in 31 CGD patients and 23 healthy control (HC) 
subjects; percentage levels (A), absolute counts (B) 
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Figure 3. Percentage of CD5 expression on B cells in 31 
CGD patients and 23 healthy control (HC) subjects; 
percentage levels (A), absolute counts (B) 
 
compared to a median of 4.71% (range of 3.51-6.8%) 
in the HC group (p<0.0001). The same direction was 
found when we compared the absolute count of the 
CD27 positive cells between the group of the patients 
and HC (Figure 1B). Two XL-CGD carriers showed 
almost the same levels of CD27+/CD19+ cells (1.56% 
and 2.12%) as XL-CGD patients. 
Moreover, the percentage ofIgD+/CD27- naïve B 
cells in peripheral blood B lymphocytes was 
significantly higher in the patients compared to the HC 
group (Figure 2A and 2B; p=0.009). There was a 
median of 14.6% (range of 2.5-32.06%) IgD+/CD27- 
cells in the patients compared to a median of 9.1% 
(range of 3.54-14.04%) in the HC group. The levels of 
IgD+/CD27- lymphocytes in the patients was 
significantly correlated with their age; patients with 
older age had lower percentage of IgD+/CD27- 
lymphocytes (Spearman’s rho= -0.40, p=0.02) as well 
as lower number of IgD+/CD27- lymphocytes 
(Spearman’s rho= -0.63, p<0.0001). The percentage of 
naïve B cells was 20.5 and 8.5 in the two XL-CGD 
carriers.  
In addition to the higher levels of naïve B cells, a 
significant higher level of CD5/CD19 positivity was 
also observed in the patients (p=0.001) (Figure 1C). A 
median of 3.52% (range from 1.76 to 6.54%) of B 
lymphocytes in the patients was CD5 positive, 
compared to a median of 2.5% (ranged from 1.52 to 
3.81%) in the HC group (p=0.001) as shown in figure 
3A while figure 3B compares absolute counts of the 
CD5 positive cells between the two groups. Along with 
the percentage results, there was a significantly higher 
level of absolute count of the CD5 positive cells in the 
patients compared to the HC (p<0.0001). The levels of 
CD5 positive lymphocytes in the patients was 
significantly correlated with their age; patients with 
older age had higher percentage of CD5 positive 
lymphocytes (Spearman’s rho= 0.55, p=0.001). 
However, this age dependency was not found when 
absolute count of the CD5 positive cells was considered 
for analyzing this correlation. The percentage of CD5+ 
cells was 3.87 and 3.21 in the two XL-CGD carriers. 
We did not find any significant difference between 
subtypes of CGD patients regarding any levels of B 
lymphocyte phenotypes (data not shown). 
 
Serum Levels of sCD27 and Immunoglobulins 
We assayed sCD27 concentration in serum of 29 
CGD patients and 16 HC subjects. The patients did not 
show any significant difference in the sCD27 levels 
compared to HC (p=0.094; mean±sd of 76.79±24.59 
U/ml in CGD patients versus 64.37±20.72 U/ml in 
HC). 
The level of CD27+ expression on B cells in the 
patients was negatively correlated with the sCD27 
levels (Spearman’s rho=-0.45 and p=0.015) (Figure 4) 
which can indicate lower CD27+ levels is because of 
their conversion to sCD27 secretion in serum. 
Moreover, to determine increase of immunoglobulin 
levels along with sCD27, we measured IgA, IgG  
and IgM levels and compared their levels with sCD27 
concentration of patients’ serum. As serum  
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* The normal range in the age groups has been cited from: 
Table 36, p154.19 
 
immunoglobulin concentrations are age
thus we classified the patients to the age groups (
2).  
We found that 12 of 31 CGD patients had above 
normal levels of IgG concentration, 13 of 31 CGD 
patients had IgA concentration above normal levels and 
all of the patients had IgM concentration in
levels. The mean of each immunoglobulin in the CGD 
patients compared to the normal range are shown in 
table 2 by the age groups. As it is shown in the table, 
all of the age groups in the CGD patients had 
approximately normal mean of the IgM lev
the mean levels of IgA was higher than the normal 
range in almost all age groups of the patients (9
years had an exception). Likewise, most age groups 
(except 1-2 years and adults) had above normal range 
of the mean levels of IgG. 
There was no significant correlation between the 
levels of sCD27 and any of the immunoglobulins (IgG, 
IgA or IgM). 
 
Figure 4. Correlation between CD27 expression and 
sCD27 serum concentrations in CGD patients
P=0.015
rs=-0.45
M. Mohsenzadegan, et al. 
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In the present study, we investigated subpopulations 
of B cells in peripheral whole blood
patients and 23 HC with approximate equal sex ratio 
(female/male ratio of 1.2 in patients and 1.3 in HC 
group) and similar age range.  
We immunophenotypically investigated memo
cells by using CD27 as a memory marker of B cells and 
naïve B cells by using IgD. We found an alteration of 
peripheral B cells: a significantly lower level of 
memory B cells and higher levels of naïve B cells in
CGD patients compared to HC. These find
that deficiency of NADPH oxidase components can 
affect the differentiation of naïve B cells to memory B 
cells and especially influence the expression of CD27 
on memory B cells. Indeed, there might be a
in conversion of naïve B cells to memory B cells in 
CGD patients. Regarding the responsible mechanism, it 
has been demonstrated that the NADPH oxidase
components (mostly p47phox) in B cells may be 
involved in a system other than the
producing NADPH oxidase and play a role in
signaling system and activation of some transcription 
factors in B cells.7 In accordance with our findings,
Bleesing et al showed profound reduction in the 
contribution of CD27+ B cells to the
compartment in CGD patients 
correlation with the defective NADPH oxidase 
system.20 Reduced CD27+ B cells has been also shown 
in patients with other immunodeficiency disorders like 
CVID13,21 and XHIM.22 In these diseases, crucial 
signaling molecules inducing terminal differentiation 
into memory B cells was suggested to be causative 
 
 





















 peripheral B cell 
and showed its 
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factor.13 In CGD, one possible causative factor is 
alteration of CD40/CD40L (CD154) which affects the 
production of memory B cells in germinal centers in 
CGD patients.14 The signaling through the 
CD40/CD40L system, a crucial element in the 
generation of memory B cells, may be adversely 
affected in patients with CGD. The reduced CD154 
expression in T lymphocytes as well as CD40 
expression on neutrophils has been shown in CGD 
patients.14 There is a connection between O2– generated 
by NADPH oxidase and CD40L induction.14 
Deficiency in productions of NADPH oxidase in CGD 
patients might therefore indirectly affect the production 
of memory B cells, impair differentiation of naïve B 
cells to memory B cells and cause reduced memory B 
cells. 
We also found higher levels of CD5 positive cells 
(B1a cells) in CGD patients compared to HC group. 
The secretion of autoantibodies in some autoimmune 
diseases has identified B-1a cells (CD5+) as potential 
contributors to the development of these kinds of 
diseases, such as lupus and discoid lupus. The 
increased B1a cells in Sjogren's syndrome and 
rheumatoid arthritis has been also reported.23 B1a cells 
are the major source of natural antibodies, which are 
serum poly-reactive and weakly autoreactive. Several 
mechanisms have been suggested to explain the 
possible role of B-1a cells in autoimmune pathogenesis, 
such as production of pathogenic autoantibodies, 
presentation of self-antigens to autoreactive T cells, 
and/or their ability to secret cytokines such as IL-10. 
15,24
 We found higher levels of CD5+ B cells (B1a 
cells) in CGD patients which is in accordance with 
previous reports indicating increased frequency of 
discoid and systemic forms of lupus in CGD patients 
and the X-linked carriers.15,20 The number of XL-CGD 
carriers in our study was not enough to compare their 
CD5+ cells levels with HC statistically but still its 
levels in two studied carriers was high and almost at the 
same levels as that found in CGD patients. Elevated 
levels of CD5+ B cells in CGD patients may explain 
the increased frequency of autoimmune diseases in 
these patients and may connect this finding to 
deficiency of NADPH oxidase in the B cells of CGD 
patients. 
Regarding the changes in the expression of the B 
cell markers by the age of our patients, we only found 
decreased percentage as well as absolute number of 
IgD+/CD27- (naïve B-cells), but not other studied 
markers. This finding is in line with the previous study 
showing decreased percentage of naïve B cells with 
age.25 
We did not find significantly increased levels of 
sCD27 in CGD patients compared to HC group 
suggesting decreased CD27 expression is not resulted 
from a specific lack of CD27 expression on B cells. 
Regarding immunoglobulins, we did not find any 
significant alteration in IgM levels in CGD patients (its 
levels was in the normal range). Besides, some patients 
had slightly higher levels of IgG and IgA than the 
normal range suggesting likely presence of systemic 
and mucosal infections in these patients, consistent 
with increased levels of IgG and IgA, respectively. 
Along with these findings, Carnide et al reported 
hypergammaglobulinemia as a common occurrence in 
18 CGD patients26. This finding in CGD patients may 
contribute in the defense against opportunistic 
infections and persistence of inflammation. However, 
we can not speculate that CGD and other 
immunodeficiency disorders like XHIM and CVID 
share a similar pathogenic mechanism. Besides, serum 
IgG, IgA, and IgM levels were found to be essentially 
within normal limits in the CGD patients studied by 
Bleesing et al.20 
The mature B cell differentiation and 
immunoglobulin production are regulated by at least 
two of the major cell to cell signaling pathways. As 
expressed above, CD40/CD154 interactions act in an 
early phase of B cell activation and induce the 
expansion of a memory B cell pool14. It was also 
demonstrated that memory B cells are differentiated 
into plasma cells by the activated helper T cells via 
CD27/CD70 in the presence of several cytokines such 
as IL-10 and IL-2.27,28 These findings strongly suggest 
that memory B cells are necessary to produce large 
amounts of immunoglobulins by differentiating into 
plasma cells through the contact with CD70.22 Serum 
sCD27 levels may therefore be important in diseases 
characterized by abnormalities in B-cell differentiation 
or activation. It has been shown that the levels of serum 
sCD27 in primary Sjogren’s syndrome patients increase 
and correlate with the elevated serum IgG 
concentrations. This suggests that the plasma cells or B 
cells undergoing plasma cell differentiation may be 
responsible for the production of both sCD27 and IgG. 
Consequently, elevation of serum sCD27 and 
hypergammaglobulinemia could be because of an 
increased plasma cell differentiation (as the main 
M. Mohsenzadegan, et al. 
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source of sCD27).29 We found negative correlation 
between expression of CD27 and sCD27 secretion in 
the CGD patients and hypergammaglobulinemia in 
some of the patients. These could result from 
differentiation of memory B cells to plasma cells in 
these patients. However, we did not find significantly 
increased sCD27 levels parallel to elevated 
immunoglobulin levels (IgG, IgA). Future 
investigations with larger group of the patients may 
clarify hypergammaglobulinemia with unknown causes 
and deficiency of NADPH oxidase in adaptive immune 
system in CGD patients. 
However, our findings suggest a role for NADPH 
oxidase enzyme in the process of B cell differentiation. 
It can phenotypically affect subsets of B cells and 
impair conversion of naïve B cells to memory B cells in 
CGD patients. This can play an important role in these 
patients to be more susceptible to recurrent infections. 
Additionally increased CD5+ B cells in these patients 
can be an explanation for higher frequency of 
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